Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
about
Modulating splicing with small molecular inhibitors of the spliceosomeMicrobial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer TreatmentTargeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate-dependent dioxygenase.Enantioselective synthesis of spliceostatin E and evaluation of biological activity.The spliceosomal PRP19 complex of trypanosomesSplicing function of mitotic regulators links R-loop-mediated DNA damage to tumor cell killingNovel and emerging targeted-based cancer therapy agents and methods.Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A.Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC statusSmall Molecule Modulators of Pre-mRNA Splicing in Cancer TherapyInterchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stagesFunctional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Test-firing ammunition for spliceosome inhibition in cancer.RNA splicing factors as oncoproteins and tumour suppressors.Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.Design, synthesis and in vitro splicing inhibition of desmethyl and carba-derivatives of herboxidienePre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1.Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.Therapeutic targeting of splicing in cancer.Splicing factor gene mutations in hematologic malignancies.Modulation of aberrant splicing in human RNA diseases by chemical compounds.RNA processing as an alternative route to attack glioblastoma.Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.Basal-A Triple Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival.A Challenging Pie to Splice: Drugging the Spliceosome.PRPF8 is important for BRCA1-mediated homologous recombination.Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.Splicing Factor Mutations in Cancer.A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.RQN-18690A (18-deoxyherboxidiene) targets SF3b, a spliceosome component, and inhibits angiogenesis.
P2860
Q26738664-21432F05-E17B-4656-B515-ED20039DA1C6Q28074931-D861A722-B0A7-4C95-83A6-CB1B48F73CCAQ34047259-4E1F2DEB-51DC-4735-89C2-7EB7EA6490ECQ34082976-A40CF4EC-BCD0-49E8-88D8-43D0A8E9D645Q34661764-DCC3F9FC-A1FF-4AD3-94A8-D87B8DFCF6FFQ35218927-CFD0C167-FF7B-4BAE-B651-7A836E8A6339Q35543181-0236CC70-C138-4CA4-A72F-0BA48CD08852Q35558057-53214FF9-FD09-4879-9564-2D313D47ED16Q35619558-4C2A26AB-475B-454C-AD1B-7F1765974E59Q35800840-A863FBE7-2D68-4EBA-8E17-B47936E99FF5Q36165982-1FEFCB52-DDB0-45EF-B9B9-B429492A98B2Q36278557-BCC87B44-1D68-49BE-8E17-7F93987966DAQ36447664-53929C55-EB60-4CC1-9AF8-6315873F9074Q36566585-20002DF5-F57A-496C-A6F2-3A2E0A8B55EAQ36584775-18E7F502-6805-495C-8A45-18D84B75F835Q36984373-389CAB89-5306-4E62-BE07-E9E98917F960Q37339144-CA035B50-620C-4BAA-B661-E8F1CC26E1C9Q37391660-666B1D9D-0035-466F-9B07-FB07483A11F0Q37511674-6DAB69FC-F464-4A9F-811C-096196305D2FQ37677391-C8E4CE98-6D26-49D6-BDC7-2F2326736FCCQ38286217-5251C347-2098-4CD3-90E7-CC8AEB85F7C8Q38646974-1867F13E-5AFA-4C65-9935-7F46795B80CCQ38712211-6AF3D041-E7AD-4256-840E-365D7D97D916Q38716479-C346122B-8630-45A1-BF2E-B699F5FE6D5FQ38735423-158376B5-8C9A-4952-8CFC-E64E03E0DAF6Q38948363-681A6DCC-98A6-4007-907E-4BF8F0F29EDBQ39035441-28EE3C58-7C5B-4219-8B72-0C3D96D1C144Q39212263-5BCC15FC-E0EA-4227-BD45-976054FDB95BQ39368650-F93361AF-DE80-4FFA-847D-16EF0663890BQ41091296-060174FD-C0B0-446A-AB2C-2800A748D8F5Q42222741-A15D4253-A566-4884-986B-3859A786ABE2Q42338844-CEF33377-B21E-4523-BF0A-82E810D05BB1Q42514519-E11B8012-AF37-4909-AF07-71FD25F2A022Q46298922-A5EDA5BD-2041-4567-AD3E-99CC546B65D5Q47096369-1F25BDAD-4EF1-4705-9E15-805ED3B93143Q48103666-8F857E28-2EBE-40C3-9E88-B9F0050EC7A5Q50803287-9A934D5C-5EBE-4EF9-A2A6-49361E0A69B4Q51220040-C4407E9B-9131-4186-9D0C-393216B220C6Q52313265-4603B800-E881-4711-A3B7-139A549355D5Q52918561-6C25C820-9E3D-43F7-85CC-C0CD5E4CE240
P2860
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@ast
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@en
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@nl
type
label
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@ast
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@en
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@ast
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@en
Phase I pharmacokinetic and ph ...... ts with advanced solid tumors.
@nl
P2093
P50
P1476
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@en
P2093
Adelaida Piera
Ferry A L M Eskens
Herman Burger
James P O'Brien
José Baselga
Maja J A de Jonge
Maria Josepa Carreras
Yoshiharu Mizui
P304
P356
10.1158/1078-0432.CCR-13-0485
P407
P577
2013-08-27T00:00:00Z